Skip to content
DataLookout
Menu

NCT07594548

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Start date changed from estimate of Sep 9, 2027 to Nov 10, 2026
    • Site details revised at 2 of 2 sites
  2. Notable Eligibility criteria expanded, about 59 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Study description revised
    • Site contacts updated at 2 of 2 sites
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Maximum tolerated dose
Timeframe: From cycles 1 day 8 (start of Futibatinib) to cycle 2 day 8 (cycle length = 28 days)
Recommended phase 2 dose
Timeframe: Up to 2 years

Secondary (5)

Incidence of adverse events
Objective response rate
Duration of response (DOR)
Progression free survival (PFS)
Overall survival (OS)

Arms and interventions

Treatment (futibatinib, paclitaxel, ramucirumab)Experimental

Patients receive ramucirumab IV over 30-60 minutes on days 1 and 15 of each cycle, paclitaxel IV over 60 minutes on days 1, 8 and 15 of each cycle, and futibatinib PO QD on days 8-28 of cycle 1 and days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI, and optional blood and urine sample collection throughout the study.

Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging

Drugs: Futibatinib, Paclitaxel

Biologicals: Ramucirumab

Sites

2 sites in 1 country